Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

AVT32-DRL_PB · AVT32

Other · developed by Alvotech Swiss

Phase 1 Most advanced trial

ALVO Developer

1 Registered trials

What is AVT32-DRL_PB?

AVT32-DRL_PB is an agent given intravenously at 200 mg every 3 weeks, studied in melanoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: AVT32
Drug type: Other
Therapy area: Oncology
Developer: Alvotech Swiss AG (ALVO)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07475572	Phase 1	Melanoma	Recruiting	ALVO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Melanoma

More from Alvotech Swiss

AVT03 Phase 3 AVT04 Phase 3 AVT05 Phase 3 AVT06 Phase 3 AVT16 Phase 3 AVT29 Phase 3 AVT80 Phase 1

Sources

ClinicalTrials.gov NCT07475572

Updated Oct 11, 2026. Something wrong or missing? Report it on the ALVO page.

Follow ALVO, the company behind AVT32-DRL_PB

See ALVO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ALVO catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z